Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $493.1 million.

  • Mirum Pharmaceuticals' Total Liabilities rose 1312.32% to $493.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $493.1 million, marking a year-over-year increase of 1312.32%. This contributed to the annual value of $445.1 million for FY2024, which is 1185.15% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Total Liabilities stood at $493.1 million for Q3 2025, which was up 1312.32% from $470.7 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Total Liabilities peaked at $493.1 million during Q3 2025, and registered a low of $88.4 million during Q1 2021.
  • In the last 5 years, Mirum Pharmaceuticals' Total Liabilities had a median value of $365.0 million in 2023 and averaged $307.5 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Total Liabilities surged by 72726.05% in 2021 and then surged by 900.97% in 2025.
  • Mirum Pharmaceuticals' Total Liabilities (Quarter) stood at $174.4 million in 2021, then rose by 20.88% to $210.9 million in 2022, then soared by 88.72% to $398.0 million in 2023, then rose by 11.85% to $445.1 million in 2024, then grew by 10.77% to $493.1 million in 2025.
  • Its last three reported values are $493.1 million in Q3 2025, $470.7 million for Q2 2025, and $457.0 million during Q1 2025.